CTOs on the Move


 
Suvoda’s sole focus is to offer the industry’s leading SaaS solution for randomization and trial supply management. Suvoda’s Interactive Response Technology (IRT/IWRS) combines the flexibility of a custom solution with the speed of a configurable platform, offering 4-week deployment, reimagined reporting, and easy integration.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.suvoda.com
  • 181 Washington Street Suite 100
    Conshohocken, PA USA 19428
  • Phone: 855.788.6321

Executives

Name Title Contact Details
Scot LeVan
Vice President of Global Information Technology Profile

Funding

Suvoda raised $40M on 12/05/2019

Similar Companies

ViroChem Pharma

ViroChem Pharma is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healthpoint Biotherapeutics

Healthpoint Biotherapeutics is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Independent Living Inc. Pediatric Therapy Tampa FL

FREE developmental screening! Tampa, St. Petersburg, Wesley Chapel clinic and school based pediatric therapy services. Physical, Occupational, Speech, Applied Behavioral Analysis

Fuse Medical

Fuse Medical, Inc., formerly Golf Rounds.com, Inc., is engaged in marketing, distributing and selling internal fixation, bone materials, biologics, tissues, surgical and other related surgical products. The Company operates through medical products and...

Theseus Pharmaceuticals

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).